Fabry disease revisited: Management and treatment recommendations for adult patients
- PMID: 29530533
- DOI: 10.1016/j.ymgme.2018.02.014
Fabry disease revisited: Management and treatment recommendations for adult patients
Abstract
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the "classic" phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.
Keywords: Diagnosis; Fabry disease; Management; Mutation; Treatment.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13. Mol Genet Metab. 2016. PMID: 27510433 Clinical Trial.
-
Fabry Disease and the Heart: A Comprehensive Review.Int J Mol Sci. 2021 Apr 23;22(9):4434. doi: 10.3390/ijms22094434. Int J Mol Sci. 2021. PMID: 33922740 Free PMC article. Review.
-
An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease.Mol Genet Metab. 2022 Sep-Oct;137(1-2):49-61. doi: 10.1016/j.ymgme.2022.07.010. Epub 2022 Jul 26. Mol Genet Metab. 2022. PMID: 35926321 Review.
-
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.Mol Genet Metab. 2018 Feb;123(2):154-158. doi: 10.1016/j.ymgme.2017.10.001. Epub 2017 Oct 5. Mol Genet Metab. 2018. PMID: 29055531 Clinical Trial.
-
Genetics and Gene Therapy of Anderson-Fabry Disease.Curr Gene Ther. 2018;18(2):96-106. doi: 10.2174/1566523218666180404161315. Curr Gene Ther. 2018. PMID: 29618309 Review.
Cited by
-
Exploring the Link between Cardiorenal and Metabolic Diseases.Healthcare (Basel). 2023 Oct 26;11(21):2831. doi: 10.3390/healthcare11212831. Healthcare (Basel). 2023. PMID: 37957976 Free PMC article.
-
Nail-patella-like renal disease masquerading as Fabry disease on kidney biopsy: a case report.BMC Nephrol. 2020 Aug 13;21(1):341. doi: 10.1186/s12882-020-02012-3. BMC Nephrol. 2020. PMID: 32791958 Free PMC article.
-
Diagnosing Fabry nephropathy: the challenge of multiple kidney disease.BMC Nephrol. 2023 Nov 21;24(1):344. doi: 10.1186/s12882-023-03388-8. BMC Nephrol. 2023. PMID: 37990184 Free PMC article. Review.
-
Clinical characteristics and induced pluripotent stem cells (iPSCs) disease model of Fabry disease caused by a novel GLA mutation.QJM. 2024 Aug 1;117(8):566-573. doi: 10.1093/qjmed/hcae038. QJM. 2024. PMID: 38429952 Free PMC article.
-
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.Drugs. 2021 Nov;81(17):1969-1981. doi: 10.1007/s40265-021-01621-y. Epub 2021 Nov 8. Drugs. 2021. PMID: 34748189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical